NASDAQ:HRMY

Harmony Biosciences Holdings Stock Insider Trading

Healthcare > Biotechnology

Buy HRMY

*Your capital is at risk

$35.24

-0.620 (-1.73%)

At Close: Jul 31, 2026

Harmony Biosciences Holdings Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 26.17. In total, the insiders bought 1.86M and sold 13.43M HRMY shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	26.17
● Buy	1.86M shares
● Sell	13.43M shares
77% Buy Activity Weak Positive Correlation
Buy Signal Medium Confidence Jul 16, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 26.17. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (77% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Aug 15, 2025 Sell	Common Stock S-Sale	Kapadia Sandip Chief Financial Officer	C-Suite Officer	21 573 Value: $787.4K
Aug 15, 2025 Sell	Common Stock S-Sale	Kapadia Sandip Chief Financial Officer	C-Suite Officer	21 573 Value: $787.4K
May 25, 2025 Buy	Stock Option A-Award	Graf R. Mark Director	Director	14 522 Value: $497.1K
May 25, 2025 Buy	Stock Option A-Award	Graf R. Mark Director	Director	14 522 Value: $497.1K
May 15, 2025 Buy	Stock Option A-Award	Sabater Juan A. Director	Director	14 522 Value: $497.1K
May 15, 2025 Buy	Stock Option A-Award	Gracias Antonio J. Director	Director	14 522 Value: $497.1K
May 15, 2025 Buy	Stock Option A-Award	Philip Ron M Director	Director	14 522 Value: $497.1K
May 15, 2025 Buy	Stock Option A-Award	Szyper Linda M Director	Director	14 522 Value: $497.1K
May 15, 2025 Buy	Stock Option A-Award	Anastasiou Peter Director	Director	14 522 Value: $497.1K
May 15, 2025 Buy	Stock Option A-Award	Sender Gary Director	Director	14 522 Value: $497.1K
May 15, 2025 Buy	Stock Option A-Award	Sender Gary Director	Director	14 522 Value: $497.1K
May 15, 2025 Buy	Stock Option A-Award	Anastasiou Peter Director	Director	14 522 Value: $497.1K
May 15, 2025 Buy	Stock Option A-Award	Szyper Linda M Director	Director	14 522 Value: $497.1K
May 15, 2025 Buy	Stock Option A-Award	Philip Ron M Director	Director	14 522 Value: $497.1K
May 15, 2025 Buy	Stock Option A-Award	Gracias Antonio J. Director	Director	14 522 Value: $497.1K
May 15, 2025 Buy	Stock Option A-Award	Sabater Juan A. Director	Director	14 522 Value: $497.1K
May 01, 2025 Buy	Restricted Stock Units M-Exempt	Budur Kumar Chief Medical Officer	Officer	18 750 Value: $559.9K
May 01, 2025 Buy	Common Stock M-Exempt	Budur Kumar Chief Medical Officer	Officer	18 750 Value: $559.9K
May 01, 2025 Sell	Common Stock F-InKind	Budur Kumar Chief Medical Officer	Officer	8 869 Value: $264.8K
May 01, 2025 Sell	Common Stock F-InKind	Budur Kumar Chief Medical Officer	Officer	8 869 Value: $264.8K
May 01, 2025 Buy	Common Stock M-Exempt	Budur Kumar Chief Medical Officer	Officer	18 750 Value: $559.9K
May 01, 2025 Buy	Restricted Stock Units M-Exempt	Budur Kumar Chief Medical Officer	Officer	18 750 Value: $559.9K
Apr 07, 2025 Buy	Stock Option A-Award	Zaeske Adam H. Chief Commercial Officer	Officer	100 000 Value: $2.84M
Apr 07, 2025 Buy	Common Stock J-Other	Zaeske Adam H. Insider	Other	0 Value: $0
Apr 07, 2025 Buy	Restricted Stock Units A-Award	Zaeske Adam H. Chief Commercial Officer	Officer	30 000 Value: $852.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT HARMONY BIOSCIENCES HOLDINGS, INC.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmo...

Read Full Profile Here